Western blotting results showed a higher PD‐L1 expression rate due to its higher sensitivity, which may partly illustrate why some tumor patients with PD‐L1‐negative tumors could still have a significant response to a PD‐L1 inhibitor, which is probably related to sensitivity. Here, CD274 is linked to neoplasm.